Literature DB >> 1715967

Spontaneous electrical activity regulates vasoactive intestinal peptide expression in dissociated spinal cord cell cultures.

D V Agoston1, L E Eiden, D E Brenneman, I Gozes.   

Abstract

Activity-dependent expression of vasoactive intestinal peptide (VIP) was investigated in spinal cord/dorsal root ganglia cultures derived from embryonic mice. Since all spinal cord neurons appear to exhibit spontaneous action potentials after one week in vitro, activity-dependent regulation of VIP-transcripts (mRNAVIP) could be studied with or without electrical blockade induced by tetrodotoxin (TTX). In 10-day-old cultures, a 50% decrease in mRNAVIP was observed after 3 days of treatment with TTX. The decrease in mRNAVIP was reversed upon removal of the TTX and was dependent on the age of the cultures: no decreases from control were observed in 5-day-old cultures and much smaller decrements were produced in one month old cultures treated with TTX. A variety of neuroactive substances were tested for effects on mRNAVIP in electrically active and electrically blocked cultures. Application of 8-bromo-cAMP (cAMP), N-methyl-D-aspartate (NMDA), substance P, muscimol, A23187 and VIP to electrically active cultures resulted in a 2- to 3-fold increase in mRNAVIP, while phorbol myristate 13-acetate (PMA) and 8-bromo-cGMP (cGMP) had no effect. In contrast, electrically inactive cultures exhibited a 3 to 4-fold increase in mRNAVIP after treatment with PMA, cAMP and VIP, while NMDA, substance P, muscimol, A23187 and cGMP produced no increases. In summary, the regulation of VIP gene expression in embryonic spinal cord neurons shows a temporal sensitivity to TTX-induced electrical blockade and may be mediated by multiple neurotransmitter inputs which converge on cAMP- and calcium-related processes in an activity-dependent manner.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1715967     DOI: 10.1016/0169-328x(91)90066-7

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  11 in total

1.  VIP, from gene to behavior and back: summarizing my 25 years of research.

Authors:  Illana Gozes
Journal:  J Mol Neurosci       Date:  2008-07-08       Impact factor: 3.444

2.  A femtomolar-acting neuroprotective peptide.

Authors:  D E Brenneman; I Gozes
Journal:  J Clin Invest       Date:  1996-05-15       Impact factor: 14.808

3.  Protection against developmental deficiencies by a lipophilic VIP analogue.

Authors:  I Gozes; M Bachar; A Bardea; A Davidson; S Rubinraut; M Fridkin
Journal:  Neurochem Res       Date:  1998-05       Impact factor: 3.996

Review 4.  A new concept in the pharmacology of neuroprotection.

Authors:  I Gozes; D E Brenneman
Journal:  J Mol Neurosci       Date:  2000 Feb-Apr       Impact factor: 3.444

Review 5.  Regulation of VIP gene expression in general. Human lung cancer cells in particular.

Authors:  A Davidson; T W Moody; I Gozes
Journal:  J Mol Neurosci       Date:  1996       Impact factor: 3.444

Review 6.  Activity-dependent neurotrophic factor (ADNF). An extracellular neuroprotective chaperonin?

Authors:  I Gozes; D E Brenneman
Journal:  J Mol Neurosci       Date:  1996       Impact factor: 3.444

Review 7.  VIP as a cell-growth and differentiation neuromodulator role in neurodevelopment.

Authors:  J M Muller; V Lelievre; L Becq-Giraudon; A C Meunier
Journal:  Mol Neurobiol       Date:  1995 Apr-Jun       Impact factor: 5.590

Review 8.  Neuropeptides as growth and differentiation factors in general and VIP in particular.

Authors:  I Gozes; D E Brenneman
Journal:  J Mol Neurosci       Date:  1993       Impact factor: 3.444

9.  Learning and sexual deficiencies in transgenic mice carrying a chimeric vasoactive intestinal peptide gene.

Authors:  I Gozes; J Glowa; D E Brenneman; S K McCune; E Lee; H Westphal
Journal:  J Mol Neurosci       Date:  1993       Impact factor: 3.444

10.  Expression of neuropeptides and neuropeptide mRNAs in spinal cord after axotomy in the rat, with special reference to motoneurons and galanin.

Authors:  X Zhang; V M Verge; Z Wiesenfeld-Hallin; F Piehl; T Hökfelt
Journal:  Exp Brain Res       Date:  1993       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.